Ongoing Clinical Trials

Indication
Institution
Department
Principal Investigator
Protocol Title
TMU-JIRB No. Protocol Title Indication Institution Department Principal Investigator Contact
N202402003 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A Nephropathy (IgAN) Nephropathy SHH Nephrology Mai-Szu Wu Yun-Hui Wang
0972223815
N202206023 A PHASE 3 RANDOMIZED CONTROLLED STUDY OF RENAL AUTOLOGOUS CELL THERAPY (REACT) IN SUBJECTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE (REGEN-006) Diabetes and Chronic Kidney Disease SHH Nephrology Mai-Szu Wu Yun-Hui Wang
0972223815
N201810016 A Phase III, Double-blind, Placebo controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN) Lung Cancer SHH Pulmonary Medicine Kang-Yun Lee Rong-Wei Jhou
0963969166
N201903127 A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer Lung Cancer SHH Pulmonary Medicine Kang-Yun Lee Rong-Wei Jhou
0963969166
N201912030 A Phase 3, Randomized, Doubleblind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemothera py plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab o r Placebo for Participants with Resectable Stage II-IIIB Non-small Cell Lung Cancer Lung Cancer SHH Pulmonary Medicine Kang-Yun Lee Cing-Mei Chen
0970746955
N202004125 A Phase III, Randomised, Controlled, Multi-centre, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer (NeoADAURA) Lung Cancer SHH Pulmonary Medicine Kang-Yun Lee Cing-Mei Chen
0970746956
N202005083 A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination with AB122, and AB154 in Combination with AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer Lung Cancer SHH Pulmonary Medicine Kang-Yun Lee Rong-Wei Jhou
0963969166
N202005083 A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination with AB122, and AB154 in Combination with AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer Lung Cancer SHH Pulmonary Medicine Kang-Yun Lee Rong-Wei Jhou
0963969166
N202005126 A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC) Lung Cancer SHH Pulmonary Medicine Kang-Yun Lee Rong-Wei Jhou
0963969166
N202009060 A Phase II, Single Arm Study Assessing the Efficacy of Osimertinib in Combination with Savolitinib in Patients with EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer who have Progressed Following Treatment with Osimertinib (The SAVANNAH Study) Lung Cancer SHH Pulmonary Medicine Kang-Yun Lee Rong-Wei Jhou
0963969166
1 2 3 4 5 6 7 8 9 10 11 12 13 / 13

TOP